Shionogi’s Brisk Crestor Sales Help It Buck Industry Tide Of Lower Earnings
This article was originally published in PharmAsia News
Executive Summary
TOKYO - Bolstered by strong global sales of its blockbuster cholesterol agent Crestor, marketed by AstraZeneca, Shionogi forecast Nov. 5 that it expected a 20 percent profit jump for the full business year ending next March. The company stands out among leading Japanese drug makers for reporting income gains for both the full year and half-year ended in September